Please login to the form below

Not currently logged in
Email:
Password:

aducanumab

This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Another amyloid-targeting treatment, Biogen’s aducanumab, is currently being reviewed by the US Food and Drug Administration (FDA). ... However, due to the lack of new treatments for Alzheimer’s emerging in the last decade, it may still approve

Latest news

More from news
Approximately 15 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    The preponderance of the data indicates aducanumab doesn’t provide a clinical benefit,’ Skorney wrote in a note to investors. ... If, after receiving input from an advisory committee, the FDA decides to approve aducanumab, it will provide an

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics